Envista (NVST) Competitors $15.63 +0.17 (+1.10%) As of 04/14/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVST vs. PEN, STVN, GKOS, NARI, INSP, BLCO, SLNO, IRTC, PRCT, and TMDXShould you be buying Envista stock or one of its competitors? The main competitors of Envista include Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Envista vs. Penumbra Stevanato Group Glaukos Inari Medical Inspire Medical Systems Bausch + Lomb Soleno Therapeutics iRhythm Technologies PROCEPT BioRobotics TransMedics Group Envista (NYSE:NVST) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Does the media refer more to NVST or PEN? In the previous week, Envista had 1 more articles in the media than Penumbra. MarketBeat recorded 16 mentions for Envista and 15 mentions for Penumbra. Penumbra's average media sentiment score of 0.60 beat Envista's score of 0.53 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Penumbra 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Is NVST or PEN more profitable? Penumbra has a net margin of 1.17% compared to Envista's net margin of -44.56%. Penumbra's return on equity of 9.74% beat Envista's return on equity.Company Net Margins Return on Equity Return on Assets Envista-44.56% 3.86% 2.21% Penumbra 1.17%9.74%7.35% Does the MarketBeat Community believe in NVST or PEN? Penumbra received 797 more outperform votes than Envista when rated by MarketBeat users. Likewise, 80.29% of users gave Penumbra an outperform vote while only 33.33% of users gave Envista an outperform vote. CompanyUnderperformOutperformEnvistaOutperform Votes3433.33% Underperform Votes6866.67% PenumbraOutperform Votes83180.29% Underperform Votes20419.71% Which has more risk and volatility, NVST or PEN? Envista has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Do analysts recommend NVST or PEN? Envista presently has a consensus target price of $20.18, indicating a potential upside of 29.10%. Penumbra has a consensus target price of $293.80, indicating a potential upside of 8.50%. Given Envista's higher possible upside, research analysts plainly believe Envista is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Envista 2 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 Do insiders & institutionals have more ownership in NVST or PEN? 88.9% of Penumbra shares are held by institutional investors. 1.3% of Envista shares are held by insiders. Comparatively, 5.0% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, NVST or PEN? Penumbra has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnvista$2.51B1.07-$1.12B-$6.49-2.41Penumbra$1.19B8.77$90.95M$0.34796.41 SummaryPenumbra beats Envista on 15 of the 19 factors compared between the two stocks. Remove Ads Get Envista News Delivered to You Automatically Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVST vs. The Competition Export to ExcelMetricEnvistaDental equipment & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$2.69B$3.74B$5.35B$18.51BDividend YieldN/A2.65%5.11%4.25%P/E Ratio-2.4141.7921.7531.06Price / Sales1.071.39380.5126.47Price / Cash12.916.5738.1517.54Price / Book0.920.606.434.29Net Income-$1.12B-$153.72M$3.20B$1.02B7 Day Performance6.15%2.97%9.08%6.72%1 Month Performance-5.99%-16.43%-6.04%-6.79%1 Year Performance-18.42%-36.29%10.66%1.22% Envista Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVSTEnvista4.3947 of 5 stars$15.63+1.1%$20.18+29.1%-18.5%$2.69B$2.51B-2.4112,700Analyst RevisionGap UpPENPenumbra3.8568 of 5 stars$263.59+0.5%$294.47+11.7%+24.5%$10.15B$1.19B775.253,900Short Interest ↑Gap UpSTVNStevanato Group1.7165 of 5 stars€19.23+1.1%N/A-24.1%$5.82B$1.10B40.914,650Positive NewsGKOSGlaukos4.5779 of 5 stars$85.87+2.7%$163.25+90.1%-5.3%$4.86B$383.48M-29.92780Gap UpHigh Trading VolumeNARIInari Medical0.3514 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.6412 of 5 stars$149.72+5.5%$226.70+51.4%-35.4%$4.46B$802.80M86.541,246Positive NewsGap DownBLCOBausch + Lomb3.9812 of 5 stars$11.86-2.1%$18.82+58.7%-14.0%$4.18B$4.79B-13.0312,500Gap DownSLNOSoleno Therapeutics4.7936 of 5 stars$69.64+3.2%$99.63+43.1%+88.5%$3.19BN/A-20.9830Analyst ForecastPositive NewsHigh Trading VolumeIRTCiRhythm Technologies0.9164 of 5 stars$100.17-0.2%$119.73+19.5%-8.8%$3.15B$591.84M-27.521,790Positive NewsPRCTPROCEPT BioRobotics2.3789 of 5 stars$50.83-0.8%$94.29+85.5%+6.0%$2.79B$224.50M-26.07430Positive NewsGap DownHigh Trading VolumeTMDXTransMedics Group2.7537 of 5 stars$69.15+2.2%$122.70+77.4%-5.4%$2.33B$441.54M73.56210Gap Up Remove Ads Related Companies and Tools Related Companies Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Inari Medical Alternatives Inspire Medical Systems Alternatives Bausch + Lomb Alternatives Soleno Therapeutics Alternatives iRhythm Technologies Alternatives PROCEPT BioRobotics Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NVST) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Envista Holdings Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Envista With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.